Digest Network Come funziona
Network
/
Società
Id
Non verificato

Idorsia Pharmaceuticals Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione Aziendale

92 comunicati stampa

Guarda tutti i comunicati
03/11/2026
Farmaceutica
Annunci Economici
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
02/11/2026
Farmaceutica
Annunci Economici
Invitation to Idorsia's webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
28/10/2026
Farmaceutica
Annunci Economici
Management/Organizzazione Aziendale
Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
28/10/2026
Farmaceutica
Annunci Economici
Finanza
Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
27/10/2026
Farmaceutica
Annunci Economici
Management/Organizzazione Aziendale
Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
26/10/2026
Farmaceutica
Annunci Economici
Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
25/10/2026
Farmaceutica
Annunci Economici
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
23/10/2026
Farmaceutica
Annunci Economici
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/10/2026
Farmaceutica
Annunci Economici
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/10/2026
Farmaceutica
Annunci Economici
New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0